| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
An2 Therapeutics, Inc. (ANTX) has 14 insiders with recent SEC Form 4 filings, including 2 buys and 13 sells. ANTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 92.0K | $483.9K | - | |
| Dir | 79.1K | $416.0K | - | |
| Other | 66.6K | $350.2K | -265 | |
| Other | 59.1K | $310.8K | - | |
| Other | 58.0K | $304.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | Easom Eric74 | Chief Executive Officer | Buy | 50,000 | $1.00 | $49,970.00 | +4.9% | +14.0% | +12.0% | |
| Aug 14, 2024 | Leonard Braden Michael60 | 10% Owner | Buy | 1,500,000 | $1.04 | $1,560,000.00 | +35.3% | +1.0% | +0.5% | |
| Aug 9, 2024 | Ra Capital Management, L.P.53 | 10% Owner | Sell | 3,525,094 | $1.08 | $3,807,101.52 | -63.5% | +6.8% | +4.9% | |
| Jan 18, 2024 | Zakrzewski Joseph S55 | Director | Sell | 100,000 | $19.11 | $1,911,410.00 | -19.8% | -87.5% | -93.6% | |
| Jan 16, 2024 | Adjuvant Global Health Technology Fund, L.P.73 | 10% Owner | Sell | 100,000 | $19.65 | $1,965,000.00 | -4.0% | -87.7% | -93.8% | |
| Jan 16, 2024 | Aziz Kabeer73 | Director | Sell | 100,000 | $19.65 | $1,965,000.00 | -4.0% | -87.7% | -93.8% | |
| Jan 12, 2024 | Readnour Robin Shane52 | Director | Sell | 1,425 | $21.91 | $31,228.81 | -0.2% | -85.6% | -94.0% | |
| Jan 10, 2024 | Readnour Robin Shane52 | Director | Sell | 3,669 | $21.93 | $80,443.17 | -0.4% | -85.4% | -94.0% | |
| Jan 9, 2024 | Krause Kevin Michael | Chief Strategy Officer | Sale+OE | 7,417 | $20.14 | $149,367.25 | -79.5% | -86.0% | -94.0% | |
| Jan 2, 2024 | Krause Kevin Michael | Chief Strategy Officer | Sale+OE | 2,583 | $20.12 | $51,967.12 | -57.4% | -81.1% | -93.0% |